<DOC>
	<DOCNO>NCT02274753</DOCNO>
	<brief_summary>Colorectal cancer lead cancer sex combine . They represent 15-20 % cancer . This cancer severe prognosis , survival rate 5 year around 55 % France estimate , colorectal cancer responsible annual mortality 15,000 patient . The prognosis colon cancer know significant improvement . The treatment colon cancer surgical . It intend removal colonic segment bear tumor margin healthy colon . The therapeutic attitude follow surgery essentially driven histopathology tumor . Adjuvant chemotherapy patient localize stage II provide benefit effectiveness chemotherapy limit vulnerable systemic toxicity . However , nearly 30 % patient stage II disease recurrence / metastasis . These patient could benefit adjuvant chemotherapy . Intense research effort make identify marker predictive relapse . Over thirty biological marker ( eg . Mutations , deletion , chromosomal instability , ... ) highlight . None far sufficient prognostic value ( independent TNM ) justify routine application clinical practice order adapt treatment patient . The identification new prognostic marker major issue colorectal cancer . We show intratumoral density memory T lymphocytes ( CD45RO ) cytotoxic ( CD8 ) strongly influence clinical outcome patient . We develop validate `` immunoscore '' technique intratumoral immune quantification create platform facilitate clinical immuno transfer . We currently conduct large international retrospective study ( 22 center , &gt; 9000 patient ) promotion cancer immunotherapy Company ( SITC ) validate method `` immunoscore . '' At time , conduct prospective multicenter study `` ImmuCol '' ( National PHRC ) validate prognostic value `` immunoscore '' colorectal cancer stage I-IV . The goal inclusion achieve , 420 patient include 18 month . Clinical follow-up 3 year surgery . The program ImmuCol2 research take advantage ImmuCol study extend investigation beyond immunoscore define combination interest , prognostic theranostic parameter diagnosis clinical course patient objective personalized medicine .</brief_summary>
	<brief_title>Personalizing Colorectal Cancer Medicine ( ImmuCol2 )</brief_title>
	<detailed_description>The project aim : ( ) combine time diagnosis immunoscore parameter related patient , tumor associate microenvironment ( ii ) detect event occur follow period could modify initial prognosis lead reposition patient , move towards dynamic personalized medicine . ( iii ) explore Theranostic aspect parameter monitor time diagnosis patient colonic cancer treat adjuvant chemotherapy . To end investigate : - Tumor 's feature : - We determine microsatellite instability status search mutation 46 gene ( ABL1 , AKT1 , ALK , APC , ATM , BRAF , CCDH1 , CDKN2A , CSF1R , CTNNB , EGFR , ERBB2 , ERBB4 , EZH2 , FBXW7 , FGFR1 , FGFR2 , FGFR3 , FLT3 , GNA11 , GNAQ , GNAS , HNF1A , HRAS , IDH1 , IDH2 , JAK2 , JAK3 , KDR , KIT , KRAS , NOTCH1 , NPM1 , NRAS , PDGFRA , PDGFRA , PIK3CA , PTEN , PTPN11 , RB1 , RET , SMAD4 , SMARCB1 , SMO , STK11 , TP53 , VHL ) next generation sequencing ( NGS ) . - Tumor immune microenvironment feature : - 24 immune relate gene , 24 miRNA co-inihibitory molecule ( PD1 , PD1-L , LAG-3 , TIM3 , CTLA-4 ) explore tumor sample . - Systemic disorder : - Autoimmunity , allergy inflammatory disease seek dedicate questionnaire fill patient serum examination screen immune disorder time diagnosis survey . - The nutritional status ( % weight loss ) deficiencies vitamin , folic acid , trace element thyroid hormone synergise immune cell determine time diagnosis . - Psychological status : - The impact psychological profile patient investigate dedicated questionnaire , give time diagnosis every six month . - Data mining achieve dynamic personalized medicine : The integration statistical analysis heterogeneous data type ( clinical different experimental data ) perform use tranSMART , open source platform bioinformatic tool ( TMEdb , ClueGO , CluePedia , Genesis ) develop participant team .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Adult patient newly diagnose colon cancer Patient sign informed consent Patient followup first three year make recruit center Adjuvant treatment ( chemotherapy ) start time inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>